EUVIMEDOpdag EUVIMED
Multizentrische StudieVergleichsstudieBeobachtungsstudieKohortenstudie

Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study

Yan Liu iD, Xue Liu, Dongyuan Sun, Ruoxi Gu, Meicen Li, Xiaozeng Wang iD

Catheterization and Cardiovascular Interventions · 2026-04 · 107 (5) · 1562-1572

DOI: 10.1002/ccd.70503 ↗

At a glance

Multizentrische Studie in Catheterization and Cardiovascular Interventions, published online on 2026-02-08. Written by Yan Liu and 5 co-authors. Institution: Department of Cardiology, National Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, General Hospital of North…. Major MEDLINE topics: Ticagrelor, Clopidogrel, Platelet Aggregation Inhibitors, Aspirin. Cited 1 times so far (Crossref); 46 references. Funded by: Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Mega Project on Major Infectious Disease Prevention.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The safety and efficacy of aspirin combined with ticagrelor or clopidogrel remain unclear in ST‐segment elevation myocardial infarction (STEMI) patients with Diabetes mellitus (DM) and poor glycemic control.

Aims

This study aims to assess the efficacy and safety of ticagrelor versus clopidogrel–based dual antiplatelet therapy in STEMI patients with DM and poor glycemic control undergoing pPCI.

Methods

We evaluated 2732 STEMI patients with DM and poor glycemic control who underwent primary percutaneous coronary intervention (pPCI) and were registered in the “Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome (CCC‐ACS)” program between November 2014 and December 2019. Using propensity score matching (PSM) and cox proportional hazards regression, we compared the in‐hospital risk of major adverse cardiovascular events (MACCE), TIMI bleeding events, and net adverse clinical events (NACE) between patients receiving aspirin combined with either ticagrelor or clopidogrel.

Results

After PSM, the risk of in‐hospital MACCE (HR = 0.545, 95% CI: 0.321–0.926, p = 0.025), Cardiac death (HR = 0.380, 95% CI: 0.149–0.971, p = 0.043) and NACE (HR = 0.728, 95% CI: 0.560–0.947, p = 0.018) was significantly lower in the ticagrelor group compared with the clopidogrel group ( p < 0.05), while no significant difference was observed in the incidence of TIMI‐bleeding events between the two groups ( p > 0.05).

Conclusion

Among STEMI patients with DM and poor glycemic control undergoing pPCI, ticagrelor use was associated with a low rate of MACCE, without an excessive risk of bleeding. Trial Registration The information of clinical trial registration for CCC‐ACS project can be found at http://clinicaltrials.gov/study/NCT02306616 .

Subjects

MeSH terms (MEDLINE)

TicagrelorClopidogrelPlatelet Aggregation InhibitorsAspirinPercutaneous Coronary InterventionST Elevation Myocardial InfarctionGlycemic ControlDiabetes MellitusBlood GlucoseDual Anti-Platelet TherapyHumansFemaleMaleRetrospective StudiesTreatment OutcomeMiddle AgedTime FactorsRisk FactorsChinaAgedRisk AssessmentBiomarkersGlycated HemoglobinHemorrhageRegistries

Author keywords

ST‐segment elevation myocardial infarctionclopidogreldiabetes mellitusglycated hemoglobin A1chyperglycemiaticagrelor

Substances

TicagrelorClopidogrelPlatelet Aggregation InhibitorsAspirinBlood GlucoseBiomarkersGlycated Hemoglobinhemoglobin A1c protein, human

Authors and institutions

  • Department of Cardiology, National Key Laboratory of Frigid Zone Cardiovascular Disease, Cardiovascular Research Institute, General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
  • School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.

ORCID profiles: Yan Liu, Xiaozeng Wang

Funding

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Mega Project on Major Infectious Disease Prevention

Cite

APA

Liu, Y., Liu, X., Sun, D., Gu, R., Li, M., & Wang, X. (2026). Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study. Catheterization and Cardiovascular Interventions, 107(5), 1562-1572. https://doi.org/10.1002/ccd.70503

Vancouver

Liu Y, Liu X, Sun D, Gu R, Li M, Wang X. Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study. Catheterization and Cardiovascular Interventions. 2026;107(5):1562-1572. doi:10.1002/ccd.70503

BibTeX
@article{Liu2026,
  author = {Liu, Yan and Liu, Xue and Sun, Dongyuan and Gu, Ruoxi and Li, Meicen and Wang, Xiaozeng},
  title = {Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  volume = {107},
  number = {5},
  pages = {1562--1572},
  doi = {10.1002/ccd.70503}
}
Start for free →